The research found that there was no clear appropriate analogue to benchmark the assets strategy against which resulted in a re-focusing of the project on the identification of innovative payment models to best support the assets value focus.
Inbeeo’s client, a major global pharmaceutical company, is commercializing an ultra-orphan drug in a rare neurodegenerative disorder. The client asked Inbeeo to help them define their pricing strategy in a new and much larger target population following new clinical data.
The new indication potentially represented an unprecedented increase in the size of the treated population for an ultra-orphan product.
HOW WE APPROACHED THE CHALLENGE
Inbeeo selected analogues based on a deep understanding of the product’s attributes and the uniqueness of its market access and pricing challenges.
Proximity indicators were largely independent from the indication, which is the most commonly used dimension in analogue studies.